AI-generated · cited to primary sources · not investment advice · How we research
Cipla
Our verdict on Cipla isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
Cipla delivered $226 million in North America revenue for Q1 FY26, slightly exceeding the $220 million guidance provided in the previous quarter. (1 exceeded, 1 in progress, 2 met, 1 revised across 5 tracked commitments)
“We also signed an agreement to launch Cipla's first biosimilar in the U.S. expected in quarter 2 FY '26, a key milestone that marks our entry into this high potential segment.”
Management has increased R&D intensity to 7.1% of revenue in Q2 FY26, up from the 6.2% level in the previous quarter, reflecting an upgrade in investment commitment. (1 revised, 1 met across 2 tracked commitments)
“The R&D spend that we had planned for the year, so now that we are estimating the R&D spend for the entire year now as against the plan, what we had planned, the spend will be about 0.5% -- sorry, I may have said 500 basis points, I meant 50 basis points, 0.5% of revenue higher basically.”
The re-inspection of the Indore facility is still pending but expected to occur imminently. (1 in progress across 1 tracked commitment)
“We expect the reinspection of our Indore facility any time in this year and the early next.”
Management plans to launch two major respiratory products and one smaller respiratory launch within the next 6 months. — target: 3 respiratory launches (+4 more commitments)
“So, effectively, I think what is immediate, let's say from 0 to 6 months, we are calling for, from 0 to 6 months, two big respiratory launches, and one smaller launch, right, on respiratory.”
Cipla has already recruited and trained a dedicated field force for the upcoming tirzepatide launch. — target: Dedicated field force
“Actually, the field force has already added, recruited and has been trained. So we have been doing that over the past 3 to 4 months.”
See the full cited Management analysis of Cipla
How durable is the business?
The EMEU business has officially entered a growth phase after four years of stability, driven by deep market penetration and expansion in both direct-to-market (DTM) and business-to-business (B2B) categories. (5 expanding across 1 engine)
“In EMEU, we delivered our fourth successive quarterly revenue above $100 million, recording a 7% YOY growth in USD terms.”
The company's cash position has strengthened significantly, reaching over $1 billion in net cash, providing a massive buffer for future growth investments. (2 expanding across 1 engine)
“We reported a quarterly revenue of Rs 7,074 crores, which is flat YOY. The EBITDA margin, excluding other income, stood at 17.7%, to be precise for the quarter.”
The company maintains a very healthy net cash position of over INR 10,000 crores after debt, providing significant 'dry powder' for potential M&A and continued R&D investment. (2 stable, 1 expanding, 2 shifted)
“R&D investments for the quarter was Rs 494 crores at about 7% of revenue. This was a growth of 37.4% YOY... net cash equivalent balance at Rs. 10,229 crores.”
North America revenue is contracting due to the planned exit of generic Revlimid (Lenalidomide) and unexpected supply disruptions for Lanreotide following a partner facility inspection. (1 contracting)
“In North America, we delivered quarterly revenue of $167 million... We faced certain supply challenge in some of our key products and increased competition in new launches.”
North America revenue was $167 million, facing some pressure from the decline of generic Revlimid and supply challenges for Lanreotide. — North America (19.8% revenue share) (+1 more finding)
“In North America, we delivered quarterly revenue of $167 million, which included a small contribution from Lenalidomide. We faced certain supply challenge in some of our key products and increased competition in new launches”
See the full cited Business Model analysis of Cipla
Where does growth come from?
Profitability is showing a strong upward trend. EBITDA margins improved from 24.5% in FY24 to 25.9% in FY25. The final quarter (Q4) showed a significant 150 basis point improvement compared to the same period last year, driven by better product mix and operating efficiency. (2 accelerating, 2 steady across 4 signals, 1 leading indicator)
“we entered into a strategic agreement with Pfizer for exclusive marketing and distribution rights of four well-established Pfizer brands in India. We also signed a definitive agreement to acquire Inzpera Health Sciences”
Cipla is actively expanding and de-risking its manufacturing footprint. This includes a recently capitalized China facility and preparing two U.S. facilities to supply respiratory products (MDI/DPI). (1 new trend across 1 signal, 1 leading indicator)
“let's say from 0 to 6 months, we are calling for... two big respiratory launches, and one smaller launch, right, on respiratory... Then we have peptide launches... in the 6 months to 12 months trajectory.”
The India business is showing an improving growth trend, recovering from a slower Q1. Branded prescriptions grew 8% while chronic therapies like urology and dermatology saw high double-digit growth. (1 accelerating, 1 decelerating, 3 steady across 5 signals)
“Our One-India business delivered a strong quarter with 10% year-on-year growth... Our overall chronic mix further strengthened to 62.3% YOY.”
Cipla is expanding its diabetes treatment options in India through a partnership with Eli Lilly to launch a modern once-weekly injection for obesity and diabetes.
“through our partnership with Eli Lilly, we launched Yurpeak, a modern once-weekly tirzepatide therapy for obesity and type 2 diabetes”
Cipla is actively building capacity and diversifying its manufacturing base to ensure supply resilience. The China facility is now fully utilized for US supplies, and the company is maximizing capacity for key products like Albuterol to gain market share. (1 accelerating across 1 signal)
“it’s a perpetual license that we have got for the trademark and we can also manufacture it in-house... we will have the benefit of own manufacturing and therefore full supply chain margins.”
See the full cited Future Growth analysis of Cipla
What could break the thesis?
The risk is intensifying as management explicitly guides for a 'compression' in Revlimid (lenalidomide) revenue over the next 2-3 quarters as it loses exclusivity, which will drag down overall margins. (1 intensifying)
“But you also have to see the next 2 or 3 quarters is when we will see a compression in lena. And that will be offset by these new products that are coming up.”
The regulatory risk profile for Indian facilities is easing significantly as 5 major Indian sites (Patalganga, Kurkumbh, Goa, Virgonagar, Medispray) were recently classified as VAI (Voluntary Action Indicated), meaning they are in good standing. (3 easing, 1 stable)
“the U.S. FDA audited 5 of our manufacturing facilities based in India... and all of these inspections have been classified as VAI.”
Margins have stabilized and shown recovery, with EBITDA margin reaching 25.6% in Q1FY26, significantly higher than the previously reported 17.7%. (2 easing)
“Profitability Momentum Continues with Strong EBITDA Margin at 25.6%”
Margins have significantly improved and stabilized. FY25 EBITDA margin reached 25.9% (up 139 bps YoY), far exceeding the previous guidance of 21%. (1 easing)
“EBITDA % 25.9% 139 bps (vs FY24); PAT % 19.1% 301 bps (vs FY24)”
The risk is easing as management reports that supplies have resumed, volumes in Q4 were significantly higher than Q3, and the product is returning to 'normalcy' in the US channel. (4 easing)
“I think on Lanreotide, as I mentioned, this quarter is -- the quarter that went by, quarter 4, was significantly higher than quarter 3 and -- in terms of volume. And also this quarter, we are coming back to normalcy.”
See the full cited Risk analysis of Cipla
Read the full thesis on Cipla
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.